MWNA
AMAG

Marshall Wace North America’s AMAG Pharmaceuticals AMAG Stock Holding History

Marshall Wace North America’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-90,085
Closed -$1.62M – 1714
2017
Q3 		$1.62M Buy
+90,085
New +$1.68M 0.01% 849
2013
Q4 		$359K Buy
+14,784
New +$348K 0.01% 571

Other funds holding AMAG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Marshall Wace North America's AMAG Position: Q4 2017 in Review

Marshall Wace North America sold out of AMAG Pharmaceuticals (AMAG) in Q4 2017, closing a stake of 90,085 shares — an estimated $1.62M sold.

Marshall Wace North America first reported a position in AMAG in Q4 2013 and held it in 2 quarters. The position peaked at $1.62M in Q3 2017. 170 funds tracked by Wall St. Rank hold AMAG as of Q4 2017.

  • Marshall Wace North America reported no remaining AMAG Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Marshall Wace North America sold 90,085 AMAG Pharmaceuticals shares in Q4 2017, an estimated $1.62M.
  • Marshall Wace North America first reported a position in AMAG Pharmaceuticals in Q4 2013 and held it in 2 quarters.
  • Marshall Wace North America's AMAG Pharmaceuticals position peaked at $1.62M in Q3 2017.
  • 170 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2017.

Based on Marshall Wace North America's 13F filing for Q4 2017, filed 14 Feb 2018.